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OBJECTIVES: Traditional celiac disease guidelines recommend follow-up endoscopy and duodenal biopsies at 6–12 months
after commencing a gluten-free diet (GFD). However, histology may remain abnormal even 1–2 years later. We evaluated the role
of capsule endoscopy in patients with celiac disease after treatment with a GFD.
METHODS: Twelve adult patients with newly diagnosed celiac disease were prospectively enrolled. All patients had baseline
symptom assessment, celiac serology (tissue transglutaminase antibody, tTG), and capsule endoscopy. Twelve months after
commencing a GFD, patients underwent repeat symptom assessment, celiac serology, upper gastrointestinal endoscopy, and
capsule endoscopy.
RESULTS: At baseline, capsule endoscopy detected endoscopic markers of villous atrophy in the duodenum and extending to a
variable distance along the small intestine. On the basis of small bowel transit time, the mean±s.e.m. percentage of small
intestine with villous atrophy was 18.2±3.7%. After 12 months on a GFD, repeat capsule endoscopy demonstrated mucosal
healingfromadistaltoproximaldirection,andthepercentageofsmallintestinewithvillousatrophy wassigniﬁcantlyreducedto
3.4±1.2% (P¼0.0014) and this correlated with improvement in the symptom score (correlation 0.69, P¼0.01). There was a
signiﬁcant improvement in symptom score (5.2±1.0 vs. 1.7±0.4, P¼0.0012) and reduction in immunoglobulin A–tTG levels
(81.5±10.6 vs. 17.5±8.2, P¼0.0005). However, 42% of subjects demonstrated persistent villous abnormality as assessed by
duodenal histology.
CONCLUSIONS: After 12 months on a GFD, patients with celiac disease demonstrate an improvement in symptoms, celiac
serology,andthe extentofdisease asmeasuredbycapsuleendoscopy.Mucosalhealingoccurs inadistal toproximaldirection.
The extent of mucosal healing correlates with improvement in symptoms. Duodenal histology does not reﬂect the healing that
has occurred more distally.
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INTRODUCTION
Celiac disease is a common disease in the Western world,
1,2
characterized by injury to the small intestine after ingestion of
gluten in genetically susceptible individuals. A strict, life-long
gluten-free diet (GFD) is the mainstay of treatment. Gluten
withdrawal from the diet is associated with improvement
in symptoms, disappearance of celiac antibodies and histo-
logical recovery.
3,4
After commencing a GFD, symptoms improve within weeks
and celiac antibodies may normalize within 6–12 months.
4
Guidelines have traditionally recommended that after com-
mencing a GFD, follow-up endoscopy and biopsies should
be performed to document the histological improvement and
to conﬁrm the clinical remission and dietary compliance.
3,5
Follow-up endoscopy after 6–12 months on a GFD is
considered as the gold standard in evaluating dietary
compliance.
6,7 However, a signiﬁcant proportion of adult
patients with celiac disease continue to have abnormal
duodenal histology even 1–2 years after starting a GFD,
4,8–13
althoughmuchofthedataareretrospectiveandcontradictory.
Failure of histological improvement is not necessarily due
to poor compliance with the GFD.
14 Failure to respond to a
GFD is associated with long-term complications, such as
osteoporosis and lymphoma.
15
In the follow-up of patients with celiac disease, commenced
on a GFD, there is poor correlation between symptom improve-
ment, normalization of celiac antibodies and histological
recovery. Negative celiac serology does not predict histo-
logical recovery as assessed by duodenal biopsy.
4,10,16–19
Therefore, in documenting mucosal recovery after commen-
cing a GFD, the extent of villous atrophy throughout the small
intestine may be more important than the severity of villous
atrophy in the duodenum. Simply performing duodenal
biopsies at 6–12 months after commencing a GFD may not
reﬂect the extent of mucosal healing that has occurred more
distally.
Capsule endoscopy is a safe and painless diagnostic
method that provides good quality images of the small
intestine, including villi. It has a high sensitivity and speciﬁcity
in detecting villous atrophy in celiac disease and is useful in
assessing the extent of small bowel involvement.
20,21 Follow-up
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www.nature.com/ctgcapsule endoscopy at least 6 months after commencing a
GFD has demonstrated that the extent of villous atrophy
improves, although the correlation with histological recovery
as assessed by duodenal biopsies is unknown.
21
The aim of this study was to evaluate the role of capsule
endoscopy in patients with celiac disease after treatment with
a GFD and to determine whether the extent of villous atrophy
throughout the small intestine as assessed by capsule
endoscopy is more important than the severity of villous
atrophy in the duodenum in assessing mucosal recovery.
METHODS
Between July 2006 and April 2009, 22 subjects with positive
celiac serology (endomysial antibody or tissue transglutami-
nase antibody (tTG)) were enrolled in a study examining the
role of capsule endoscopy in suspected celiac disease
patients with positive celiac serology.
20 In total, 8 of these
subjects had normal duodenal histology and 14 had duodenal
histology demonstrating celiac disease. This study demon-
strated that capsule endoscopy is useful in detecting villous
atrophy in untreated celiac disease, and patients with positive
celiac serology and normal duodenal histopathology are
unlikely to have capsule endoscopy markers of villous
atrophy. Following this initial study, the 14 subjects with
duodenal histology consistent with celiac disease were all
commenced on a GFD and 12 months later were invited to
participate in this follow-up study and undergo re-evaluation
with repeat symptom assessment, celiac serology, upper
gastrointestinal endoscopy, and capsule endoscopy. The
protocol was approved by the Queen Elizabeth Hospital
Ethics and Human Research Committee.
Diagnostic procedures. All subjects gave informed written
consent. The ﬁve symptoms of fatigue, abdominal bloating,
abdominal pain, diarrhea, and weight loss were prospectively
recorded and scored as 0 (absent), 1 (mild), 2 (moderate), or
3 (severe), giving a total symptom score out of 15. Blood was
taken for celiac serology (immunoglobulin A–tTG).
Subjects underwent upper gastrointestinal endoscopy and
duodenal biopsies. Biopsies were interpreted according to
the modiﬁed Marsh criteria:
22,23 Marsh I consists of raised
intraepithelial lymphocytes with 440 lymphocytes per 100
enterocytes, Marsh II consists of raised intraepithelial
lymphocytes and crypt hyperplasia, Marsh IIIa partial villous
atrophy, Marsh IIIb subtotal villous atrophy, and Marsh IIIc
total villous atrophy. Capsule endoscopy was performed
within 21 days of the upper gastrointestinal endoscopy.
Capsule endoscopy was performed using the Given PillCam
SB capsule (Given Imaging, Yoqneam, Israel). The technical
aspects have been described elsewhere.
24
Analysis of capsule endoscopy. Two investigators, with
experience in reading 4100 capsule endoscopy studies each,
reviewed the capsule endoscopy recordings. The investigators
were blinded to the subjects’ clinical information and histo-
logical ﬁndings. If there was any interobserver disagreement,
conclusion was reached by consensus. If consensus was
unable to be reached, the third investigator reviewed the
recording, although this was not required.
Endoscopic markers of villous atrophy were assessed by
analysis of capsule endoscopy ﬁndings. These endoscopic
markers include loss of mucosal folds, scalloping, mosaic
pattern,nodularity,andvisiblevessels(Figure1).Theextentof
small bowel involvement was assessed. The extent of villous
atrophy was calculated by measuring the time of villous
atrophy as a percentage of total small bowel transit time.
Statistics. Analysis comprised of summary statistics for
gender and age, comparative analysis between the ﬁndings
Figure1 (a)Capsuleendoscopyimageinapatientnewlydiagnosedwithceliac
disease, demonstrating scalloping and nodularity in the proximal jejunum. (b) After
12 months on a gluten-free diet, the proximal jejunum has returned to normal as
demonstrated by the normal villi.
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relationship of capsule endoscopy ﬁndings to clinical data.
Paired t-tests were used to compare the change in symptom
scores, change in histopathology ﬁndings and change in
the extent of villous atrophy (Marsh grade) during the
12 months follow-up period as well as comparing the
histological responders and non-responders. Pearson’s
correlation was used to calculate the correlation between
symptoms and extent of villous atrophy (as measured by
capsule endoscopy), and tTG levels. Data values were
adjusted for age, gender, and initial values. Quantitative data
were expressed as mean±s.e.m.
RESULTS
Of the 14 subjects, who were invited to participate in this
follow-up study, 1 was unwilling to participate in the study and
a second subject had died from cardiomyopathy while waiting
for a cardiac transplant. At the time of the follow-up study, the
meanage ofthe remaining 12 subjects was45 years, andfour
were men and eight were women.
Effect of 12 months on a GFD. The 12 patients had a
variety of symptoms at baseline, including fatigue, abdominal
pain, diarrhea, and anemia. Following 12 months on a GFD,
there was a signiﬁcant improvement in symptom score
(5.2±1.0 vs. 1.7±0.4, P¼0.0012).
All patients were positive to HLA-DQ2 (10 subjects), HLA-
DQ8 (1 subject), or HLA-DQB1*02 (1 subject). At baseline,
all were positive to tTG. At the 12-month-follow-up, the
tTG antibody level had normalized in 9 of the 12 subjects.
Overall, there was a signiﬁcant reduction in immunoglobulin
A–tTGlevels(81.5±10.6vs.17.5±8.2,P¼0.0005)following
a GFD.
Capsule endoscopy was performed within 21 days of
histological diagnosis of celiac disease and before commen-
cing a GFD. One subject, with Marsh IIIc duodenal histology
had a completely normal capsule endoscopy study. The other
11 subjects all had villous abnormalities in the duodenum,
extending to a variable distance along the small intestine.
On the basis of small bowel transit time, the mean±s.e.m.
percentage extent of small intestine involvement with villous
atrophy was 18.2±3.7%. Four subjects had erosions in
the small intestine (range: 1–4 erosions). These were found
in the middle third of the small intestine in one subject,
distal third in two subjects, and in both the middle and
distal thirds in one subject. After 12 months on a GFD,
repeat capsule endoscopy was performed. The cecum was
reached in all subjects during the recording time. There
was complete interobserver agreement with regards to
the extent of villous atrophy. Capsule endoscopy demon-
strated signiﬁcant mucosal healing from a distal to proxi-
mal direction, and the percentage of small intestine with
villous atrophy was signiﬁcantly reduced to 3.4±1.2%
(P¼0.0014). Of the four subjects who had erosions in the
small intestine at baseline, one subject had no erosions
at follow-up and three subjects still had erosions after
12 months on a GFD (range 1–4 erosions). In addition, a
subject with no erosions at baseline developed ﬁve erosions
in the small intestine at the follow-up capsule endoscopy
study. None of the subjects admitted to taking aspirin or
anti-inﬂammatory drugs.
At study enrollment, all subjects had to have villous atrophy
(Marsh stage III), to be eligible to participate in the study.
Biopsy samples from seven subjects were Marsh IIIc, four
were Marsh IIIb, and one was Marsh IIIa. After 12 months
on a GFD, subjects underwent repeat endoscopy and 3–6
duodenal biopsy samples were taken for histology. Out of
the 12 subjects, 5 were found to still have villous atrophy, at
least Marsh IIIa (histological ‘non-responders’), and the other
7 subjects were Marsh II, Marsh I, or Marsh 0 (histological
‘responders’) (Figure 2).
Correlation between improvement in symptoms,
serology, histology and extent of villous atrophy. At
study enrollment, there was no correlation between the
extent of villous atrophy seen at capsule endoscopy and
symptom score or celiac serology (tTG) levels. Following
12 months on a GFD, there was a signiﬁcant reduction
in the mean percentage extent of small intestine involve-
ment with villous atrophy as assessed by capsule endo-
scopy and this correlated with improvement in symptom
Marked villous atrophy IIIb
IIIc
IIIb
IIIc Absent villi
IIIa IIIa Mild villous atrophy
II II Hyperplastic crypts
Intraepithelial
lymphocytosis
0
I
0
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Follow up Baseline
Figure 2 Seven patients showed histological improvement (histological
‘responders’) after 12 months on a gluten-free diet. Five did not signiﬁcantly
improve histologically (histological ‘non-responders’) and were at least of Marsh
grade IIIa after 12 months on a gluten-free diet.
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Figure 3 Both the histological ‘responders’ and ‘non-responders’ showed
similar improvement in symptom score (P¼0.58) celiac serology levels (P¼0.53),
andextentofsmallbowelvillousatrophy(P¼0.37)after12monthsonagluten-free
diet. ELISA, enzyme-linked immunosorbent assay; IgA, immunoglobulin A; tTG,
tissue transglutaminase.
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in celiac serology (tTG) levels did not correlate with the
improvement in symptoms (correlation 0.23, P¼0.53) or
reduction in the extent of villous atrophy (correlation 0.03,
P¼0.94).
Comparison of histological ‘responders’ vs. ‘non-
responders’. Twelve months after a GFD, 7 of the 12
subjects demonstrated signiﬁcant histological improvement
and the other 5 subjects (42%) demonstrated persistent
villous atrophy (at least Marsh IIIa) as assessed by duodenal
histology. Both groups demonstrated signiﬁcant improve-
ment in symptom score, celiac serology (tTG) levels, and
reduction in the extent of villous atrophy as assessed
by capsule endoscopy. However, both the histological
‘responders’ and ‘non-responders’ showed similar improve-
ment in symptom score (P¼0.58), celiac serology levels
(P¼0.53) and in extent of villous atrophy (P¼0.37),
although the sample size is small (Figure 3).
DISCUSSION
This is the ﬁrst study to prospectively examine the correla-
tion of baseline and follow-up symptoms, celiac serology,
duodenal histology, and capsule endoscopy ﬁndings in newly
diagnosed celiac disease patients. It demonstrates that after
12 months on a GFD, mucosal healing occurs from a distal to
proximal direction and there is a signiﬁcant correlation
between extent of small bowel healing and improvement in
symptoms.
A signiﬁcant proportion of patients (5 out of 12, 42%)
demonstrated persistent villous atrophy as assessed by
duodenal histology. These ﬁve histological ‘non-responders’
had similar improvement in symptoms, celiac serology, and
reduction in the extent of villous atrophy as assessed by
capsule endoscopy, compared with the seven histological
‘responders’. Therefore, follow-up duodenal histology did
not reﬂect the healing that occurred more distally following
12 months on a GFD. This may explain why studies
demonstrate that a signiﬁcant proportion of adult celiac
disease patients continue to have abnormal duodenal
histology, despite improvements in symptoms and celiac
serology, even 1–2 years after starting a GFD.
4,8–13 We
believe that the majority of treated celiac disease patients
who demonstrate persistently abnormal duodenal histology,
despite improvement in symptoms and celiac serology are
incorrectly termed as ‘non-responders’ or ‘slow responders’.
In our study, these patients all demonstrated signiﬁcant
improvement in the extent of villous atrophy as assessed by
capsule endoscopy. The only other study to prospectively
follow-up newly diagnosed celiac disease patients, using
capsule endoscopy, also demonstrated mucosal healing from
a distal to proximal direction, 6–18 months after commencing
a GFD, although follow-up duodenal histology or symptoms
were not assessed.
21
In assessing the response to a GFD, the length of small
bowel involved with villous atrophy may be more important
than the severity of duodenal villous atrophy. Simply
performing follow-up duodenal histology is not an accurate
reﬂection of mucosal healing that has occurred more distally.
After 12 months on a GFD, our ﬁve histological ‘non-
responders’ demonstrated signiﬁcant improvement in symp-
toms, celiac serology, and the extent of villous atrophy, as
assessed by capsule endoscopy, but still had persistent
villous atrophy, (at least Marsh IIIa) on duodenal histology.
By obtaining biopsy samples from the entire length of small
bowel before and after treatment with a GFD, MacDonald
et al.
25 demonstrated that the distal small bowel rapidly
recovered before the proximal small bowel and this may
explain the rapid improvement in symptoms, despite persis-
tently abnormal duodenal biopsies. They concluded that
symptomatic improvement correlated better with the length
of small bowel involved, rather than the severity of duodenal
histology.
What is the long-term signiﬁcance of persistent villous
atrophy as assessed by duodenal histology? Holmes et al.
26
demonstrated that celiac disease is associated with an
increased risk of lymphoma and this risk is reduced with
a strict GFD. Kaukinen et al.
15 demonstrated that patients
with persistent villous atrophy, despite a GFD, may have
improvement in symptoms, but are at higher risk of
osteoporosis and lymphoma. However, this was a selective
sub-population of patients, with histologically refractory celiac
disease, comprising 1.9% of their celiac disease database,
who had been followed up for a median of 8 years (range
3–30). Rubio-Tapia et al.
27 demonstrated in a retrospective
study that documented mucosal recovery is associated with
a trend towards reduced mortality (P¼0.06).
We demonstrated a signiﬁcant correlation between extent
of small bowel healing and improvement in symptoms
following a GFD. However, the relevance of this ﬁnding is
unknown, given that the symptom score is subjective and not
validated. We were unable to demonstrate any correlation
between the extent of villous atrophy and the symptom score
at diagnosis. Using capsule endoscopy, other authors have
also been unable to demonstrate any signiﬁcant association
between length of small bowel affected by villous atrophy and
severity of symptoms in untreated celiac disease.
21,28 Given
that celiac disease patients may present with a wide variety of
symptoms, ranging from no symptoms at all to the classical
symptoms of diarrhea, steatorrhoea, lassitude, and weight
loss, it is plausible that other factors, such as genetic
susceptibility, variable immunological tolerance to gluten, or
gastrointestinal motility disturbances
29 may be important in
determining symptoms at diagnosis. Whether patients are
diagnosed through family or population screening may also
determine the severity of symptoms.
What is the role of capsule endoscopy in celiac disease
patients? Capsule endoscopy can visualize the entire length
of small intestine. It may have the potential to assess the
extent of villous atrophy at diagnosis and to document the
extentofsmall bowelhealingaftercommencingaGFD.Itmay
be useful in assessing dietary compliance and monitoring for
complications, such as intestinal lymphoma or ulcerative
jejunoileitis.
30
In summary, we have demonstrated, using capsule endo-
scopy, that after 12 months on a GFD, mucosal healing
occurs from a distal to proximal direction, and the extent
of healing along the length of the small intestine corre-
lated with improvement in the symptom score. Follow-up
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occurs more distally. Capsule endoscopy may potentially
have a valuable role in the follow-up of people with celiac
disease.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| After commencing a gluten-free diet, a signiﬁcant
proportion of adult patients with celiac disease
continue to have abnormal duodenal histology
even after 1–2 years.
| Small bowel healing occurs in a distal to proximal
direction.
| Capsule endoscopy has a high sensitivity and
speciﬁcity in detecting villous atrophy in celiac disease.
WHAT IS NEW HERE
| Capsule endoscopy is a sensitive method for
demonstrating the extent of mucosal healing
in celiac disease patients on a gluten-free diet.
| Capsule endoscopy demonstrates that the extent
of mucosal healing correlates with improvement
in symptoms.
| Follow-up duodenal histology does not reﬂect the
mucosal healing that occurs more distally.
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